Monophosphoryl lipid a attenuates radiation injury through TLR4 activation
PDF | HTML | How to cite
Metrics: PDF 1888 views | HTML 2249 views | ?
Jiaming Guo1,*, Yuanyuan Chen1,*, Xiao Lei1,*, Yang Xu1, Zhe Liu1, Jianming Cai1, Fu Gao1 and Yanyong Yang1
1Department of Radiation Medicine, Faculty of Naval Medicine, Second Military Medical University, Shanghai, 200433, P.R. China
*These authors have contributed equally to this work
Yanyong Yang, email: [email protected]
Fu Gao, email: [email protected]
Jianming Cai, email: [email protected]
Keywords: monophosphoryl lipid a (MPLA), radioprotection, toll like receptor 4 (TLR4), TRIF, MyD88
Received: June 16, 2017 Accepted: August 04, 2017 Published: September 15, 2017
Ionizing radiation causes severe damage to human body, and normal tissue toxicity in cancer radiotherapy also limits its further application. It is urgently required to develop safe and effective radioprotector. Our previous study has shown that toll like receptor 4 (TLR4) was dispensable for basal radiation resistance. However, severe toxicity of its traditional agonist lipopolysaccharide limits the clinical application. In present study, we demonstrated that monophosphoryl lipid A (MPLA), a potent TLR4 agonist with low toxicity, effectively attenuated radiation injury on in vitro and in vivo. MPLA increased cell survival and inhibited cell apoptosis after irradiation, and cell cycle arrest was also inhibited. Radiosensitive tissues including spleen, intestine, bone marrow and testis were protected from radiation damages in a TLR4 dependent manner. We also found that myeloid differentiation factor 88 (MyD88) accounted more than Toll/IL-1R domain-containing adaptor inducing IFN-β (TRIF) for the radioprotective effects of MPLA. In conclusion, our finding suggests TLR4 agonist MPLA as a safe and effective radioprotector for clinical application.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.